Sonrotoclax TFA

SKU: orb2695142

Description

Sonrotoclax TFA is a potent, selective, and orally bioavailable BCL-2 inhibitor targeting both wild-type and G101V mutant proteins. It is utilized in preclinical research for hematologic malignancies, demonstrating antitumor activity in both in vitro cellular assays and in vivo xenograft models.

Research Area

Cell Biology, Immunology & Inflammation

Key Properties

• MW: 1004.12
• Purity: >99.99% (May vary between batches)
• Formula: C₅₁H₆₀F₃N₇O₉S
• SMILES: CC(C1=C(C=CC=C1)[C@H]2N(CCC2)C3CC4(CCN(C5=CC(OC6=CN=C(NC=C7)C7=C6)=C(C=C5)C(NS(=O)(C8=CC(N(=O)=O)=C(C=C8)NC[C@@H]9CC[C@@](O)(CC9)C)=O)=O)CC4)C3)C.OC(C(F)(F)F)=O
• Target: Bcl-2 Family

Bioactivity

• In Vivo:
  A once-daily oral dose of 5-50 mg/kg Sonrotoclax TFA for 42 days exhibited antitumor activity and effectively inhibited tumor growth in a female NCG mouse model suffering from acute lymphoblastic leukemia (ALL) xenografts.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

BGB 11417 TFA, Bcl-2, Sonrotoclax TFA(2383086-06-2 Free base), SonrotoclaxTFA(2383086062Freebase)

Compound Identifiers

PubChem CID

172652817